NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03863223,A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT03863223,,UNKNOWN,"This is a randomized, double-blinded, multicenter phase 3 clinical trial to evaluate the efficacy and safety of pyrotinib plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel in patients who have HER2 positive metastatic breast cancer and have not received systemic anticancer therapy for advanced disease.",NO,Metastatic Breast Cancer,"DRUG: Pyrotinib, Trastuzumab, Docetaxel|DRUG: Placebo, Trastuzumab, Docetaxel","PFS, Progression Free Survival, Approximately 42 months","AEs+SAEs, Adverse Events and Serious Adverse Events, From the first drug administration to within 28 days for the last treatment|OS, Overall Survival, Up to 2 years|ORR, Objective Response Rate, Approximately 42 months|DoR, Duration of Objective Response, Approximately 42 months|CBR, Clinical Benefit rate, From the start of randomization to 6 months",,"Jiangsu HengRui Medicine Co., Ltd.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,590,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",HR-BLTN-III-MBC-C,2019-04-22,2022-12-30,2024-07-30,2019-03-05,,2022-11-23,"Cancer Institute and Hospital,Chinese Academy of Medical Science, Beijing, Beijing, China",
